Co-Diagnostics (CODX) rises upon good news moving forward
Co-Diagnostics (CODX) currently trades at $11.12 and has grown by 17.12% today. CODX went up $1.63 from the previous closing price of $9.50. The high forecast for Co-Diagnostics is $20.00 and the low is $5.00. The company’s market cap is $305.26 million with a 52 week high of $21.75 and a 52 week low of $0.69. CODX has changed in price by 10.08 per share in the last 12 months. The company announced today that OralDNA® Labs, a CLIA-certified laboratory, has recently validated a COVID-19 PCR test based on the Company’s patented CoPrimer™ technology for use with saline oral rinse samples, and has notified the FDA of their intent to use the validated test in their CAP accredited high-complexity laboratory.
Co-Diagnostics has a weak EPS of -0.37. This means the company lost $-0.37 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction (“PCR”) testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past.